Last reviewed · How we verify
sulopenem etzadroxil and probenecid — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
sulopenem etzadroxil and probenecid (sulopenem etzadroxil and probenecid) — Iterum Therapeutics, International Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| sulopenem etzadroxil and probenecid TARGET | sulopenem etzadroxil and probenecid | Iterum Therapeutics, International Limited | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- sulopenem etzadroxil and probenecid CI watch — RSS
- sulopenem etzadroxil and probenecid CI watch — Atom
- sulopenem etzadroxil and probenecid CI watch — JSON
- sulopenem etzadroxil and probenecid alone — RSS
Cite this brief
Drug Landscape (2026). sulopenem etzadroxil and probenecid — Competitive Intelligence Brief. https://druglandscape.com/ci/sulopenem-etzadroxil-and-probenecid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab